SMARCA2 Antibody (YA3241)(PBS only)
(Synonyms: SMARCA2; BAF190B; BRM; SNF2A; SNF2L2; Probable global transcription activator SNF2L2; ATP-dependent helicase SMARCA2; BRG1-associated factor 190B; BAF190B; Protein brahma homolog; hBRM; SNF2-alpha; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2)SMARCA2 Antibody (YA3241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SMARCA2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC
-
Reactivity :
Human, Mouse
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
FC
FC: Flow Cytometry
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:200-1:2000 | 1:20-1:50 | 1:200-1:500 |
Product Details
SMARCA2 Antibody (YA3241) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SMARCA2.
-
Host Rabbit
-
Species ReactivityHuman, Mouse
-
Observed Molecular WeightObserved band size: 190 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 181 kDa
A synthetic peptide of human SMARCA2/BRM aa62-77.
Affinity Purified
Non-conjugated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
SMARCA2 (also known as BRM) encodes one of the two mutually exclusive ATPase catalytic subunits of the mammalian SWI/SNF (BAF) chromatin-remodeling complex and regulates transcription through ATP-dependent modulation of chromatin accessibility and nucleosome positioning[1][2]. Mechanistically, SMARCA2 provides the enzymatic activity required for chromatin remodeling, thereby influencing gene-expression programs linked to cellular differentiation, proliferation, and lineage-specific transcriptional control[1][3]. Within the BAF complex, SMARCA2 functions in a paralogous relationship with SMARCA4 (BRG1), and either ATPase can support remodeling activity; however, the two proteins are incorporated in mutually exclusive complexes and can regulate distinct transcriptional programs despite substantial functional overlap[2][4]. This distinction has important disease implications because loss of SMARCA4 frequently creates a dependency on residual SMARCA2 activity, establishing a synthetic-lethal relationship that has been validated in multiple cancer models[4][5][6]. In developmental disease, recurrent SMARCA2 mutations are associated with Nicolaides-Baraitser syndrome, highlighting a nonredundant role in human development and enhancer regulation[3][7]. For experimental applications, increasing attention has focused on pharmacologic inhibition or targeted degradation of SMARCA2, particularly in SMARCA4-deficient tumors, where selective suppression of SMARCA2 produces antitumor effects and provides a tractable strategy for studying SWI/SNF ATPase dependence[5][6][8]. Studies further indicate that the ATPase domain represents a more effective therapeutic target than bromodomain inhibition alone in SWI/SNF-mutant cancer settings[6].
-
Subcellular Localization
Nucleus
-
Isoforms & Post-Translational Modification
P51531 has 2 isomers: P51531-1: 181279 Da (predicted); P51531-2: 179281 Da (predicted).
During apoptosis, cleaved by cathepsin CTSG to produce a 160 kDa cleavage product which localizes to the cytosol;Ubiquitinated -
Subunit
Component of the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. The canonical complex contains a catalytic subunit (either SMARCA4/BRG1/BAF190A or SMARCA2/BRM/BAF190B, mutually exclusive) and at least SMARCE1, ACTL6A/BAF53, SMARCC1/BAF155, SMARCC2/BAF170, and SMARCB1/SNF5/BAF47. Other subunits specific to each of the complexes may also be present permitting several possible combinations developmentally and tissue specific (Probable). Component of the BAF complex, which includes at least actin (ACTB), ARID1A/BAF250A, ARID1B/BAF250B, SMARCA2/BRM, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C (PubMed:18765789). In muscle cells, the BAF complex also contains DPF3. Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin. Interacts with PHF10/BAF45A (By similarity). Interacts with CEBPB (when not methylated) (PubMed:20111005). Interacts with TOPBP1 (PubMed:15075294). Interacts with CEBPA (when phosphorylated) (PubMed:15107404). Interacts with DPF2 (PubMed:20460684). Interacts with ERCC6 (PubMed:26030138)
-
SwissProt ID
-
Synonyms
SMARCA2; BAF190B; BRM; SNF2A; SNF2L2; Probable global transcription activator SNF2L2; ATP-dependent helicase SMARCA2; BRG1-associated factor 190B; BAF190B; Protein brahma homolog; hBRM; SNF2-alpha; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2
-
Research Field
Epigenetics and Nuclear Signaling
Documentation
References
[1]. Cantley J, et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 2022 Nov 10;13(1):6814. [Content Brief]
[2]. Vangamudi B, et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15;75(18):3865-3878. [Content Brief]
[3]. Kofink C, et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat Commun. 2022 Oct 10;13(1):5969. [Content Brief]
Powered by Bioz
